AHL Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

AHL Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$2.08M	Sell	15,461 -8,804	-36%	-$1.22M	0.03%	711
2017 Q3	$3.55M	Buy	24,265 +11,144	+85%	+$1.69M	0.06%	488
2017 Q2	$2.04M	Buy	13,121 +10,595	+419%	+$1.62M	0.04%	613
2017 Q1	$367K	Buy	2,526 +532	+27%	+$69.3K	0.01%	1049
2016 Q4	$218K	Sell	1,994 -2,122	-52%	-$236K	0.01%	1010
2016 Q3	$500K	Buy	4,116 +2,432	+144%	+$328K	0.02%	839
2016 Q2	$238K	Buy	+1,684	New	+$248K	0.01%	752
2016 Q1	–	Sell	-16,115	Closed	-$2.27M	–	793
2015 Q4	$2.27M	Buy	+16,115	New	+$2.23M	0.18%	220
2015 Q3	–	Sell	-26,940	Closed	-$4.74M	–	750
2015 Q2	$4.74M	Buy	26,940 +4,088	+18%	+$734K	0.19%	208
2015 Q1	$3.95M	Buy	22,852 +11,501	+101%	+$1.97M	0.16%	275
2014 Q4	$1.86M	Buy	+11,351	New	+$1.88M	0.1%	467

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SIG

Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

AHL Partners's JAZZ Position: Q4 2017 in Review

AHL Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 36% in Q4 2017, selling an estimated $1.22M and leaving 15,461 shares worth $2.08M. The position accounts for 0.03% of the portfolio, ranked #711.

AHL Partners first reported a position in JAZZ in Q4 2014 and has held it in 11 quarters since. The position peaked at $4.74M in Q2 2015. 323 funds tracked by Wall St. Rank hold JAZZ as of Q4 2017.

AHL Partners held 15,461 shares of Jazz Pharmaceuticals worth $2.08M as of Q4 2017.
AHL Partners sold 8,804 Jazz Pharmaceuticals shares in Q4 2017, an estimated $1.22M.
Jazz Pharmaceuticals made up 0.03% of AHL Partners's portfolio in Q4 2017, its #711 holding.
AHL Partners first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 11 quarters since.
AHL Partners's Jazz Pharmaceuticals position peaked at $4.74M in Q2 2015.
323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.